心力衰竭：药物治疗的分类综述
Heart Failure: A Class Review of Pharmacotherapy.
作者信息
Shah Ami, Gandhi Dimple, Srivastava Sneha, Shah Kunal J, Mansukhani Rupal
出版信息
P T. 2017 Jul;42(7):464-472.
Abstract
A recent guideline update for the treatment of heart failure has created the need for a new look at the medication classes and trials related to the disease. The authors focus on pharmacological options available for treating the problem.
摘要
最近一项关于心力衰竭治疗的指南更新，使得有必要重新审视与该疾病相关的药物类别和试验。作者们聚焦于可用于治疗该问题的药理学选择。
相似文献
1
Heart Failure: A Class Review of Pharmacotherapy.心力衰竭：药物治疗的分类综述
P T. 2017 Jul;42(7):464-472.
2
Pharmacological interventions for treating heart failure in patients with chagas cardiomyopathy.用于治疗恰加斯心肌病患者心力衰竭的药物干预措施。
Cochrane Database Syst Rev. 2012 Nov 14;11:CD009077. doi: 10.1002/14651858.CD009077.pub2.
3
Prescribing patterns of evidence-based heart failure pharmacotherapy and outcomes in the ASIAN-HF registry: a cohort study.基于证据的心力衰竭药物治疗的处方模式和 ASIAN-HF 注册研究的结果：一项队列研究。
Lancet Glob Health. 2018 Sep;6(9):e1008-e1018. doi: 10.1016/S2214-109X(18)30306-1.
4
The AHCPR clinical practice guideline for heart failure revisited.
Ann Pharmacother. 1997 Oct;31(10):1197-204. doi: 10.1177/106002809703101013.
5
Pharmacotherapy for posttraumatic stress disorder.创伤后应激障碍的药物治疗
Cochrane Database Syst Rev. 2000(4):CD002795. doi: 10.1002/14651858.CD002795.
6
The evolution of heart failure with reduced ejection fraction pharmacotherapy: What do we have and where are we going?射血分数降低型心力衰竭药物治疗的演变：我们拥有什么，我们要走向何方？
Pharmacol Ther. 2017 Oct;178:67-82. doi: 10.1016/j.pharmthera.2017.03.011. Epub 2017 Mar 21.
7
2019 Focused Update of the Guidelines of the Taiwan Society of Cardiology for the Diagnosis and Treatment of Heart Failure.台湾心脏病学会心力衰竭诊断与治疗指南2019重点更新版
Acta Cardiol Sin. 2019 May;35(3):244-283. doi: 10.6515/ACS.201905_35(3).20190422A.
8
[Are there any differences in guideline adherence to pharmacotherapy of heart failure between individual GP practices and Medical Care Centres (MCCs)?].
Z Evid Fortbild Qual Gesundhwes. 2010;104(2):113-9. doi: 10.1016/j.zefq.2009.11.001.
9
Key Articles and Guidelines in the Management of Heart Failure: 2018 Update.心力衰竭管理的关键文章与指南：2018年更新
J Pharm Pract. 2019 Feb;32(1):77-92. doi: 10.1177/0897190018819413. Epub 2018 Dec 19.
10
Chronic heart failure: developments and perspectives.慢性心力衰竭：进展与展望
Consult Pharm. 2005 Sep;20(9):751-65. doi: 10.4140/tcp.n.2005.751.
引用本文的文献
1
Functional and Quality of Life Outcomes in Heart Failure Patients at a Specialized Heart Failure Clinic in Dhaka, Bangladesh.孟加拉国达卡一家专业心力衰竭诊所中的心衰患者的功能及生活质量结果
Cureus. 2025 Jun 4;17(6):e85325. doi: 10.7759/cureus.85325. eCollection 2025 Jun.
2
Early prescription of quadruple therapy in acute decompensated heart failure with reduced ejection fraction: A propensity score-matched analysis.射血分数降低的急性失代偿性心力衰竭患者早期应用四联疗法：一项倾向评分匹配分析。
ESC Heart Fail. 2025 Aug;12(4):2814-2826. doi: 10.1002/ehf2.15286. Epub 2025 Apr 15.
3
Proteomic and metabolomic analyses of the human adult myocardium reveal ventricle-specific regulation in end-stage cardiomyopathies.对人类成年心肌的蛋白质组学和代谢组学分析揭示了终末期心肌病中特定于心室的调控机制。
Commun Biol. 2024 Dec 19;7(1):1666. doi: 10.1038/s42003-024-07306-y.
4
The Use of Hematopoietic Stem Cells for Heart Failure: A Systematic Review.造血干细胞治疗心力衰竭的系统评价。
Int J Mol Sci. 2024 Jun 17;25(12):6634. doi: 10.3390/ijms25126634.
5
The impact of empagliflozin and metformin on cardiac parameters in patients with mid-range ejection fraction heart failure without diabetes.恩格列净和二甲双胍对射血分数中间值的心衰伴非糖尿病患者心脏参数的影响。
J Med Life. 2024 Jan;17(1):57-62. doi: 10.25122/jml-2023-0340.
6
Omecamtiv Mecarbil in the treatment of heart failure: the past, the present, and the future.奥米卡替麦卡比治疗心力衰竭：过去、现在与未来
Front Cardiovasc Med. 2024 Mar 19;11:1337154. doi: 10.3389/fcvm.2024.1337154. eCollection 2024.
7
Beyond Quadruple Therapy and Current Therapeutic Strategies in Heart Failure with Reduced Ejection Fraction: Medical Therapies with Potential to Become Part of the Therapeutic Armamentarium.心力衰竭射血分数降低：超越四联疗法和当前治疗策略的医学治疗方法，具有成为治疗武器库一部分的潜力。
Int J Mol Sci. 2024 Mar 7;25(6):3113. doi: 10.3390/ijms25063113.
8
Evaluation of Urolithin A Efficacy in Heart Failure Patients with Reduced Ejection Fraction: A Randomized, Double-blind, Crossover, Placebo-controlled Clinical Trial.乌洛托品 A 对射血分数降低的心力衰竭患者疗效的评估：一项随机、双盲、交叉、安慰剂对照的临床试验。
Rev Recent Clin Trials. 2024;19(3):221-228. doi: 10.2174/0115748871279354240209101604.
9
Mast Cells in Cardiac Remodeling: Focus on the Right Ventricle.心脏重塑中的肥大细胞：聚焦于右心室
J Cardiovasc Dev Dis. 2024 Feb 4;11(2):54. doi: 10.3390/jcdd11020054.
10
Patterns of Digoxin Prescribing for Medicare Beneficiaries in the United States 2013-2019.2013 - 2019年美国医疗保险受益人的地高辛处方模式
Am J Med Open. 2023 Dec;10. doi: 10.1016/j.ajmo.2023.100048. Epub 2023 Jun 24.
本文引用的文献
1
Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association.《2017年心脏病和中风统计数据更新：美国心脏协会报告》
Circulation. 2017 Mar 7;135(10):e146-e603. doi: 10.1161/CIR.0000000000000485. Epub 2017 Jan 25.
2
2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America.2016年美国心脏病学会/美国心脏协会/美国心力衰竭学会关于心力衰竭新药物治疗的重点更新：2013年美国心脏病学会基金会/美国心脏协会心力衰竭管理指南更新：美国心脏病学会/美国心脏协会临床实践指南特别工作组及美国心力衰竭学会的报告
Circulation. 2016 Sep 27;134(13):e282-93. doi: 10.1161/CIR.0000000000000435. Epub 2016 May 20.
3
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.2016欧洲心脏病学会急性和慢性心力衰竭诊断与治疗指南：欧洲心脏病学会（ESC）急性和慢性心力衰竭诊断与治疗工作组编写，欧洲心脏病学会心力衰竭协会（HFA）提供特别贡献。
Eur Heart J. 2016 Jul 14;37(27):2129-2200. doi: 10.1093/eurheartj/ehw128. Epub 2016 May 20.
4
Angiotensin-neprilysin inhibition versus enalapril in heart failure.血管紧张素-脑啡肽酶抑制剂与依那普利治疗心力衰竭的比较。
N Engl J Med. 2014 Sep 11;371(11):993-1004. doi: 10.1056/NEJMoa1409077. Epub 2014 Aug 30.
5
2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines.2013年美国心脏病学会基金会/美国心脏协会心力衰竭管理指南：美国心脏病学会基金会/美国心脏协会实践指南工作组报告
Circulation. 2013 Oct 15;128(16):e240-327. doi: 10.1161/CIR.0b013e31829e8776. Epub 2013 Jun 5.
6
Lifetime risk for heart failure among white and black Americans: cardiovascular lifetime risk pooling project.美国白人和黑人的心力衰竭终身风险：心血管终身风险汇集项目。
J Am Coll Cardiol. 2013 Apr 9;61(14):1510-7. doi: 10.1016/j.jacc.2013.01.022.
7
Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study.依伐布雷定降低心力衰竭患者心率对结局的影响：β受体阻滞剂剂量是否有影响？SHIFT（伊伐布雷定治疗收缩性心力衰竭试验）研究的结果。
J Am Coll Cardiol. 2012 May 29;59(22):1938-45. doi: 10.1016/j.jacc.2012.01.020.
8
Eplerenone in patients with systolic heart failure and mild symptoms.依普利酮治疗有收缩性心力衰竭和轻度症状的患者。
N Engl J Med. 2011 Jan 6;364(1):11-21. doi: 10.1056/NEJMoa1009492. Epub 2010 Nov 14.
9
Combination of loop diuretics with thiazide-type diuretics in heart failure.心力衰竭中袢利尿剂与噻嗪类利尿剂的联合应用。
J Am Coll Cardiol. 2010 Nov 2;56(19):1527-34. doi: 10.1016/j.jacc.2010.06.034.
10
Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study.依伐布雷定治疗慢性心力衰竭的疗效评价（SHIFT）：一项随机、安慰剂对照研究
Lancet. 2010 Sep 11;376(9744):875-85. doi: 10.1016/S0140-6736(10)61198-1.
Zotero 插件